Rhythm Pharmaceuticals EBITDA vs. Total Asset
| RYTM Stock | USD 62.25 0.30 0.48% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -168.5 M | Current Value -160 M | Quarterly Volatility 70 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.8799 |
|
|
For Rhythm Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rhythm Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rhythm Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rhythm Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rhythm Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rhythm |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Rhythm Pharmaceuticals Total Asset vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rhythm Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rhythm Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Rhythm Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in total asset category among its peers . Rhythm Pharmaceuticals reported last year EBITDA of (168.46 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Rhythm Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Rhythm Total Asset vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Rhythm Pharmaceuticals |
| = | (168.46 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Rhythm Pharmaceuticals |
| = | 332.75 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Rhythm Total Asset Comparison
Rhythm Pharmaceuticals is currently under evaluation in total asset category among its peers.
Rhythm Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rhythm Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rhythm Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Rhythm Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Rhythm Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 134 K | 140.7 K | |
| Operating Income | -184.4 M | -175.1 M | |
| Income Before Tax | -184.1 M | -174.9 M | |
| Total Other Income Expense Net | 243 K | 230.8 K | |
| Net Loss | -184.7 M | -175.4 M | |
| Net Loss | -185.5 M | -176.3 M | |
| Net Loss | -163 M | -154.9 M | |
| Income Tax Expense | 564 K | 592.2 K | |
| Net Interest Income | 814 K | 1.3 M | |
| Interest Income | 13.2 M | 13.8 M | |
| Non Operating Income Net Other | 3.7 M | 3.5 M | |
| Change To Netincome | 23.4 M | 24.6 M | |
| Net Loss | (3.20) | (3.36) | |
| Income Quality | 0.74 | 0.79 | |
| Net Income Per E B T | 1.00 | 0.78 |
Rhythm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rhythm Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rhythm Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rhythm Pharmaceuticals' important profitability drivers and their relationship over time.
Use Rhythm Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rhythm Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rhythm Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Rhythm Pharmaceuticals Pair Trading
Rhythm Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Rhythm Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rhythm Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rhythm Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rhythm Pharmaceuticals to buy it.
The correlation of Rhythm Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rhythm Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rhythm Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rhythm Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Rhythm Pharmaceuticals position
In addition to having Rhythm Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
To fully project Rhythm Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rhythm Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rhythm Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.